PLSE logo

PULSE BIOSCIENCES INC

PLSENASDAQ
🏆 #1577 by market capEarnings Nov 3US Equity
$50.84▼ $1.42 (−2.80%)
Market closed · at close
🔔
Track PLSE
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.8%
7d▼ 2.1%
14d▲ 2.6%
30d▲ 1.0%
ytd▲ 269.7%
1y▲ 186.7%
🏦Market Cap
$3.52B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
-21.6%
Thin
💵FCF Margin
-5180.4%
Thin
⚖️P/S Ratio
2972.2x
Expensive
Otter Score
56
Weak

Trading Snapshot

Day Range
$50.28 – $51.66
52-Week Range
$12.56 – $58.90
Volume
$6.10B
Avg Volume
$6.92B
Shares Outstanding
69.2M
Next Earnings
Dec 16, 2026

Fundamentals Snapshot

Annual Revenue
$350,000
Last Q Revenue
$434,000
P/E Ratio
-43.5
P/S Ratio
2972.2x
EPS (TTM)
$-1.16
Dividend Yield
0.00%
Dilution (1yr)
+15.4%

Why Investors Own PLSE

  • ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PLSE logo

PULSE BIOSCIENCES INC

PLSE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$350K▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-360.0%▼ −77.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$77M▲ +36.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$54M▲ +49.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
67.4M▲ +15.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$73M▼ −$36M YoY
StockOtter · stockotter.space

About PULSE BIOSCIENCES INC

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$64.11
▲ +26.1% Upside
High Target$77.88
Low Target$58.86
Based on 23 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

PULSE BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift PLSE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

PULSE BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.